Form 8-K - Current report:
SEC Accession No. 0001628280-23-005554
Filing Date
2023-02-28
Accepted
2023-02-28 16:11:31
Documents
14
Period of Report
2023-02-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lyel-20230228.htm   iXBRL 8-K 36054
2 EX-99.1 lyel-20230228x8kexx991.htm EX-99.1 118058
6 a0000a.jpg GRAPHIC 6782
  Complete submission text file 0001628280-23-005554.txt   312345

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lyel-20230228.xsd EX-101.SCH 1899
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lyel-20230228_lab.xml EX-101.LAB 23924
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lyel-20230228_pre.xml EX-101.PRE 12594
8 EXTRACTED XBRL INSTANCE DOCUMENT lyel-20230228_htm.xml XML 11214
Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Filer) CIK: 0001806952 (see all company filings)

EIN.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40502 | Film No.: 23685377
SIC: 2834 Pharmaceutical Preparations